問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Kaoshiung Chang Gung Memorial Hospital of the C.G.M.F. (在職)

Division of Endocrinology

Kaohsiung Veterans General Hosptial (在職)

Division of Endocrinology

更新時間：2023-09-19

董石城
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

0Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

董石城

List

17Cases

2014-04-01 - 2016-06-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2019-02-15 - 2021-04-22

Phase III

Efficacy and Safety of LY3298176 Once Weekly Versus Insulin Glargine in Patients With Type 2 Diabetes and Increased Cardiovascular Risk (SURPASS-4)

  • Condition/Disease

    Type 2 Diabetes Mellitus

  • Test Drug

    LY3298176

Participate Sites
9Sites

Terminated9Sites

2019-04-01 - 2022-12-15

Phase III

A Randomized, Phase 3, Open-Label Trial Comparing the Effect of LY3298176 versus Titrated Insulin Degludec on Glycemic Control in Patients with Type 2 Diabetes (SURPASS-3)

  • Condition/Disease

    Type 2 Diabetes Mellitus

  • Test Drug

    LY3298176

Participate Sites
9Sites

Terminated9Sites

2016-07-19 - 2018-06-25

Phase III

PIONEER 6 – Cardiovascular outcomes. A trial investigating the cardiovascular safety of oral semaglutide in subjects with type 2 diabetes

  • Condition/Disease

    Type 2 Diabetes Mellitus

  • Test Drug

    Oral Semaglutide

Participate Sites
4Sites

Terminated4Sites

2013-12-01 - 2019-12-31

Phase III

Phase 3 Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Pf-04950615, In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects

  • Condition/Disease

    Major Cardiovascular Events

  • Test Drug

    PF-04950615

Participate Sites
10Sites

Terminated10Sites

2013-12-01 - 2019-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Terminated10Sites

2011-09-01 - 2020-06-18

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Not yet recruiting1Sites

Terminated3Sites

1 2
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB